hepatic encephalopathy epidemiology forecast insight

DelveInsight’s ‘Hepatic Encephalopathy—Epidemiology Forecast–2034’ report delivers an in-depth understanding of the disease, historical and forecasted Hepatic Encephalopathy epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Hepatic Encephalopathy Understanding

Hepatic encephalopathy is a brain disorder that develops in some individuals with liver disease. It is a complex disorder that encompasses a spectrum or continuum of disease that ranges from a subtle condition with no outward signs or symptoms to a severe form that can cause serious, life-threatening complications. Hepatic encephalopathy can occur in individuals with acute or chronic liver (hepatic) disease or in individuals whose liver is bypassed by a portosystemic shunt (with no liver disease present). A portosystemic shunt is an abnormal passageway that allows blood from the gastrointestinal tract to bypass the liver. They can be present at birth (congenital) or acquired during life. Hepatic encephalopathy is caused when toxins that are normally cleared from the body by the liver accumulate in the blood, eventually traveling to the brain.

It is manifested by the broad spectrum of neuropsychiatric disturbances such as defects in cognitive, emotional, behavioral, psychomotor, and locomotive functions. This condition is characterized by personality changes, intellectual impairment, and a depressed level of consciousness. The prerequisite for the syndrome is a diversion of portal blood into the systemic circulation through portosystemic collateral vessels. In patients with cirrhosis, an acute encephalopathy is most commonly associated with a precipitating factor, such as electrolyte disturbance, medications, gastrointestinal hemorrhage, or infection.

Hepatic Encephalopathy Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Number of Hepatic Encephalopathy Cases, Gender-specific Cases of Hepatic Encephalopathy, Age-Specific Cases of Hepatic Encephalopathy, and Type-Specific Cases of Hepatic Encephalopathy scenario of Hepatic Encephalopathy in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2034.

Hepatic Encephalopathy Detailed Epidemiology Segmentation

• The total number of cases of Hepatic Encephalopathy (HE) in the 7MM was estimated to be approximately 856,610 in 2020.
• Among 7MM, the United States has the highest number of cases of Hepatic Encephalopathy with about 595,090 cases in 2020.
• DelveInsight’s estimations suggest that the majority of cases of Hepatic Encephalopathy are males as compared to females. There was a total of around 432,631 male and approximately 162,460 female cases of Hepatic Encephalopathy in 2020 in the United States.
• The age‐specific data revealed that the highest number of Hepatic Encephalopathy people affected with was found in the age group of 45–54 years, while people <25 years are the least affected. There were a total of 17,853, 30,350, 96,405, 246,367, 126,159, 35,705, and 42,251 age-specific cases of Hepatic Encephalopathy in the age‐group <25 years, 25–34 years, 35–44 years, 45–54 years, 55–64 years, 65–74 years, and 75+ years in 2020 in the United States.
• In 2020, it was found that there were 357,054 cases of covert HE, and 238,036 cases of overt HE in the United States.
• In 2020 among EU-5 countries, the United Kingdom had the highest number of cases with approximately 56,099 followed by Germany with approximately 53,878 cases and France with about 44,857 cases. While Spain has the least number of cases with approximately 18,715.
• In 2020, the number of cases of Hepatic encephalopathy in Japan was found to be approximately 47,873 holding the fourth-largest epidemiology share in 7MM.

Scope of the Report

• The report covers the descriptive overview of Hepatic Encephalopathy, explaining its causes, signs, and symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.
• The report assesses the disease risk and burden.
• The report provides the segmentation of the disease epidemiology for 7MM by Number of Hepatic Encephalopathy Cases, Gender-specific Cases of Hepatic Encephalopathy, Severity-specific Cases of Hepatic Encephalopathy, and Type-specific Cases of Hepatic Encephalopathy.

Report Highlights

• 10-Year Forecast of Hepatic Encephalopathy
• 7MM Coverage
• Number of Hepatic Encephalopathy Cases
• Gender-specific Hepatic Encephalopathy Cases
• Severity-specific Hepatic Encephalopathy Cases
• Type-specific Hepatic Encephalopathy Cases

Key Questions Answered

• What are the disease risk, burdens, and unmet needs of Hepatic Encephalopathy?
• What is the historical Hepatic Encephalopathy patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Hepatic Encephalopathy at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hepatic Encephalopathy?
• Out of the countries mentioned above, which country would have the highest patient population of Hepatic Encephalopathy during the forecast period (2025-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?

Reasons to buy

The Hepatic Encephalopathy report will allow the user to:

• Develop business strategies by understanding the epidemiological trends of Hepatic Encephalopathy in the 7MM.
• Quantify patient populations in the 7MM to improve product design, pricing, and launch plans.
• The Hepatic Encephalopathy epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Hepatic Encephalopathy epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population